|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the efficacy and safety of the factor Xa inhibitor rivaroxaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) were shown in global and Japanese phase III clinical trials, safety and effectiveness data from unselected patients in everyday clinical practice are limited.
|
30745002 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Rivaroxaban is a directly acting oral anticoagulant (DOAC) that inhibits factor Xa and is widely used for stroke prevention in patients with non-valvular atrial fibrillation (AFib).
|
31263649 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF).
|
30976787 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa, and has been approved for clinical use in several thromboembolic disorders, including reduction of stroke risk in non-valvular atrial fibrillation, thromboprophylaxis following hip or knee replacement surgery, the treatment of deep vein thrombosis or pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism.
|
31089975 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
This exploratory analysis of NAVIGATE ESUS (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source) focused on patients with AAA and assessed their characteristics, stroke recurrence rates, and response to treatment.
|
31526123 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Oral factor Xa inhibitors reduced patients' risk of intracranial hemorrhage and were at least as effective in preventing stroke or systemic embolism as warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
|
31228038 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Edoxaban, a nonvitamin K antagonist oral anticoagulant, is an oral factor Xa inhibitor approved for the prevention of stroke and systemic embolism in adult patients with atrial fibrillation and for the treatment and secondary prevention in adult patients with venous thromboembolism (VTE).
|
30540648 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-Xa Activity and Event Risk in Patients With Direct Factor Xa Inhibitors Initiated Early After Stroke.
|
30210082 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
This article provides an update on three randomized controlled trials of rivaroxaban, a direct, oral factor Xa inhibitor, that are complete or are ongoing, in these unmet areas of stroke prevention: oPen-label, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention (PIONEER AF-PCI) trial; the New Approach riVaroxaban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS) trial and the Global study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement to Optimize clinical outcomes (GALILEO) trial.
|
29566416 |
2018 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among 6496 Asian patients from 6 trials, both direct thrombin inhibitors and factor Xa inhibitors, compared with warfarin, were associated with lower risks of stroke or systemic embolism and major bleeding (risk ratio [95% confidence interval], 0.51 [0.33-0.78], 0.74 ([0.58-0.96], 0.60 [0.41-0.86], and 0.59 [0.47-0.76], respectively).
|
29239808 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Substudies from 4 trials (RE-LY [Randomized Evaluation of Long-Term Anticoagulation Therapy], ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE [Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation], and ENGAGE-AF [Effective Anticoagulation With Factor xA Next Generation in Atrial Fibrillation]) were included in the meta-analysis.
|
29794081 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Direct or new oral anticoagulants (NOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, have recently revolutionized the field of antithrombotic therapy for stroke and systemic embolism prevention in nonvalvular atrial fibrillation (NVAF).
|
29975925 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
In the ATLAS-TIMI 52 trial, a low-dose direct factor Xa inhibition with rivaroxaban compared with placebo reduced the combined primary endpoint of cardiovascular mortality, myocardial infraction and stroke with an increase in major bleeding complications.
|
30103248 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Rivaroxaban, a widely used factor Xa inhibitor in reducing stroke in atrial fibrillation (AF) patients has multiple biological effects with activation of protease-activated receptor (PAR) signaling.
|
30213724 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Edoxaban is an orally active, direct factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation and for the treatment of venous thromboembolism.
|
28512699 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Factor Xa (FXa) inhibitors, used for stroke prevention in atrial fibrillation and venous thromboembolism treatment and prevention, are the dominant non-Vitamin K oral anticoagulants on the market.
|
28843518 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Edoxaban, a direct factor Xa inhibitor, is noninferior vs warfarin for the prevention of stroke or systemic embolism with less major bleeding in patients with nonvalvular AF.
|
29663464 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
In moderate- to high-risk AF patients, the direct factor Xa inhibitor edoxaban is noninferior to vitamin K antagonists (VKAs) for prevention of stroke or systemic embolism with less bleeding and cardiovascular deaths.
|
30172099 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Rivaroxaban, a direct factor Xa inhibitor, is widely used to reduce the chance of stroke in patients with atrial fibrillation (AF).
|
30244598 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Four direct oral anticoagulants (DOACs) are available for the prevention of stroke in nonvalvular atrial fibrillation (NVAF): dabigatran (a direct thrombin inhibitor); and rivaroxaban, apixaban, and edoxaban (factor Xa inhibitors).
|
28805310 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Rivaroxaban, apixaban and edoxaban are direct inhibitors of FXa approved for the management of venous thromboembolism and stroke prevention in atrial fibrillation.
|
28650000 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Edoxaban is a new oral direct factor Xa inhibitor that has been recently approved for treating VTE in patients who have already been treated with a parenteral anticoagulant and for the prevention of stroke and non-central nervous system systemic embolism in patients with nonvalvular atrial fibrillation.
|
27811198 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
In ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), the factor Xa inhibitor edoxaban was noninferior to warfarin in preventing stroke or systemic embolic events and significantly reduced bleeding and cardiovascular mortality.
|
28077507 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
As alternatives to warfarin, oral direct acting factor Xa inhibitors are currently approved for the prophylaxis and treatment of venous thromboembolism and reduction of stroke and systemic embolization.
|
28232327 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Aim The ATTICUS randomized trial is designed to determine whether the factor Xa inhibitor apixaban administered within 7 days after embolic stroke of undetermined source, is superior to acetylsalicylic acid for prevention of new ischemic lesions documented by brain magnetic resonance imaging within 12 months after index stroke.
|
27881833 |
2017 |